ELTX Share Price Performance
US$3.22
-4.69 (-59.29%)
96.8% undervalued intrinsic discount
US$100.00
Fair Value
Price US$3.22
Coward_Nutlick US$100.00
Fair ValueUS$100.00
Share Pricen/a
Elicio Therapeutics, Inc. Stock Price
- 1 Narratives written by author
- 3 Comments on narratives written by author
- 34 Fair Values set on narratives written by author
ELTX Community Narratives
CO
Fair Value
·Fair Value US$100 96.8% undervalued intrinsic discount
Very Bullish
6users have liked this narrative
3users have commented on this narrative
28users have followed this narrative
Very Bullish
Early trial results in a pancreatic cancer vaccine show most patients mounting a strong immune response, raising hopes it could help keep the disease from coming back after treatment. The next big readout could be a turning point if the larger study confirms the benefit—and a setback if it doesn’t.Read more
CO
US$100
96.8% undervalued intrinsic discount
Fair Value
Profit Margin
21.21%
Future PE
29.38x
Price in 2031
US$140.1
Trending Discussion
Recently Updated Narratives
CO
Aggressively accumulate equity shares and August 15 call options
Fair Value: US$100 96.8% undervalued intrinsic discount
28 fair values setusers have set this as their fair value
3 commentsusers have commented on this narrative
3 likesusers have liked this narrative
Snowflake Analysis
Elicio Therapeutics, Inc. Key Details
About ELTX
- Founded
- n/a
- Employees
- 33
- CEO
- WebsiteView website
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
